A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524936-20-00

Enrollment

Registered

2026-07-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of psychotic disorders like schizophrenia Treatment of levodopa-induced dyskinesia in Parkinson's disease

None listed

Sex/Gender

All

Age

18 Years to 64 Years

None listed

Source: EU CTIS · Data processed: Jul 21, 2026